These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38832951)

  • 1. Inhibition of glycolysis enhances the efficacy of immunotherapy via PDK-mediated upregulation of PD-L1.
    Zhang R; Mao G; Tang Y; Li C; Gao Y; Nie W; Song T; Liu S; Zhang P; Tao K; Li W
    Cancer Immunol Immunother; 2024 Jun; 73(8):151. PubMed ID: 38832951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulforaphane impaired immune checkpoint blockade therapy through activating ΔNP63α/PD-L1 axis in gastric cancer.
    Zhang Q; Yang C; Ma Z; Ye L; Wu Y; Zhong C; Shi Y; Zhu M
    Mol Carcinog; 2024 Aug; 63(8):1611-1620. PubMed ID: 38780147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis.
    Sun L; Huang C; Zhu M; Guo S; Gao Q; Wang Q; Chen B; Li R; Zhao Y; Wang M; Chen Z; Shen B; Zhu W
    Theranostics; 2020; 10(26):11950-11962. PubMed ID: 33204322
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
    Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
    FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 6. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
    Que Y; Zhang XL; Liu ZX; Zhao JJ; Pan QZ; Wen XZ; Xiao W; Xu BS; Hong DC; Guo TH; Shen LJ; Fan WJ; Chen HY; Weng DS; Xu HR; Zhou PH; Zhang YZ; Niu XH; Zhang X
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.
    Wu RY; Kong PF; Xia LP; Huang Y; Li ZL; Tang YY; Chen YH; Li X; Senthilkumar R; Zhang HL; Sun T; Xu XL; Yu Y; Mai J; Peng XD; Yang D; Zhou LH; Feng GK; Deng R; Zhu XF
    Clin Cancer Res; 2019 Jul; 25(14):4530-4541. PubMed ID: 30940655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy.
    Anwar S; Shamsi A; Mohammad T; Islam A; Hassan MI
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188568. PubMed ID: 34023419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CircRHBDD1 promotes immune escape via IGF2BP2/PD-L1 signaling and acts as a nanotherapeutic target in gastric cancer.
    Li Y; Wang Z; Gao P; Cao D; Dong R; Zhu M; Fei Y; Zuo X; Cai J
    J Transl Med; 2024 Jul; 22(1):704. PubMed ID: 39080693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
    Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
    Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
    Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
    Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors.
    Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S
    Front Immunol; 2021; 12():619209. PubMed ID: 33790893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
    Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
    Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin induces ferroptosis and activates anti-tumor immunity to sensitize anti-PD-1 immunotherapy in microsatellite stable gastric cancer.
    Ning Y; Fang S; Zhang R; Fang J; Lin K; Ding Y; Nie H; Zhou J; Zhao Q; Ke H; Wang H; Wang F
    Int Immunopharmacol; 2024 Dec; 142(Pt B):113244. PubMed ID: 39317047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
    Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
    Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy inhibition enhances PD-L1 expression in gastric cancer.
    Wang X; Wu WKK; Gao J; Li Z; Dong B; Lin X; Li Y; Li Y; Gong J; Qi C; Peng Z; Yu J; Shen L
    J Exp Clin Cancer Res; 2019 Mar; 38(1):140. PubMed ID: 30925913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of nucleophosmin/B23 sensitizes ovarian cancer cells to immune check-point blockade via PD-L1 in ovarian cancer.
    Tsai CL; Tang YH; Yang LY; Chao A; Wang CJ; Lin CY; Lai CH
    J Formos Med Assoc; 2024 Oct; 123(10):1045-1056. PubMed ID: 38821736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.